These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 34168403)

  • 1. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment.
    Granito A; Muratori L; Lalanne C; Quarneti C; Ferri S; Guidi M; Lenzi M; Muratori P
    World J Gastroenterol; 2021 Jun; 27(22):2994-3009. PubMed ID: 34168403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses.
    Zhang HH; Mei MH; Fei R; Liu F; Wang JH; Liao WJ; Qin LL; Wei L; Chen HS
    J Viral Hepat; 2010 Mar; 17 Suppl 1():34-43. PubMed ID: 20586932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analyses of regulatory T cell subsets in patients with hepatocellular carcinoma: a crucial role of CD25(-) FOXP3(-) T cells.
    Kakita N; Kanto T; Itose I; Kuroda S; Inoue M; Matsubara T; Higashitani K; Miyazaki M; Sakakibara M; Hiramatsu N; Takehara T; Kasahara A; Hayashi N
    Int J Cancer; 2012 Dec; 131(11):2573-83. PubMed ID: 22419479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune regulation and therapeutic application of T regulatory cells in liver diseases.
    Ajith A; Merimi M; Arki MK; Hossein-Khannazer N; Najar M; Vosough M; Sokal EM; Najimi M
    Front Immunol; 2024; 15():1371089. PubMed ID: 38571964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased frequency and FOXP3 expression of human CD8
    Zahran AM; Nafady-Hego H; Mansor SG; Abbas WA; Abdel-Malek MO; Mekky MA; Hetta HF
    Hum Immunol; 2019 Jul; 80(7):510-516. PubMed ID: 30904437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of costimulatory and inhibitory receptors in FoxP3
    Toker A; Ohashi PS
    Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis.
    Lu LC; Deantonio C; Palu CC; Lee YH; Mitchell LS; Cowan M; Corser M; Sherry L; Cheng AL; Quaratino S; Shao YY; Sainson RCA; Hsu CH
    Oncology; 2022; 100(8):419-428. PubMed ID: 35709702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis.
    Kumar P; Saini S; Prabhakar BS
    Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma (HCC) tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) tumor microenvironment.
    Santagata S; Rea G; Castaldo D; Napolitano M; Capiluongo A; D'Alterio C; Trotta AM; Ieranò C; Portella L; Di Maro S; Tatangelo F; Albino V; Guarino R; Cutolo C; Izzo F; Scala S
    Hepatol Int; 2024 Apr; 18(2):568-581. PubMed ID: 37142825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+CD25+CD127(low) Regulatory T Cells Play Predominant Anti-Tumor Suppressive Role in Hepatitis B Virus-Associated Hepatocellular Carcinoma.
    Sharma S; Khosla R; David P; Rastogi A; Vyas A; Singh D; Bhardwaj A; Sahney A; Maiwall R; Sarin SK; Trehanpati N
    Front Immunol; 2015; 6():49. PubMed ID: 25767469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Foxp3+ regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma.
    Wang F; Jing X; Li G; Wang T; Yang B; Zhu Z; Gao Y; Zhang Q; Yang Y; Wang Y; Wang P; Du Z
    Liver Int; 2012 Apr; 32(4):644-55. PubMed ID: 22118340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.
    Kobayashi N; Hiraoka N; Yamagami W; Ojima H; Kanai Y; Kosuge T; Nakajima A; Hirohashi S
    Clin Cancer Res; 2007 Feb; 13(3):902-11. PubMed ID: 17289884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma.
    Huang Y; Wang F; Wang Y; Zhu Z; Gao Y; Ma Z; Xu R; Du Z
    J Gastroenterol Hepatol; 2014 Apr; 29(4):851-9. PubMed ID: 24303990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-10 derived from Hepatocarcinoma cells improves human induced regulatory T cells function via JAK1/STAT5 pathway in tumor microenvironment.
    Zhang S; Gan X; Qiu J; Ju Z; Gao J; Zhou J; Shi C; Zhu Y; Li Z
    Mol Immunol; 2021 May; 133():163-172. PubMed ID: 33667986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies.
    González-Navajas JM; Fan DD; Yang S; Yang FM; Lozano-Ruiz B; Shen L; Lee J
    Front Immunol; 2021; 12():625783. PubMed ID: 33717139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
    Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
    Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.
    Chew V; Lai L; Pan L; Lim CJ; Li J; Ong R; Chua C; Leong JY; Lim KH; Toh HC; Lee SY; Chan CY; Goh BKP; Chung A; Chow PKH; Albani S
    Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5900-E5909. PubMed ID: 28674001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma patients.
    Li F; Guo Z; Lizée G; Yu H; Wang H; Si T
    Clin Chem Lab Med; 2014 Sep; 52(9):1357-65. PubMed ID: 24646790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.